Some brighter views
21/06/22 -"We have revised our models and included all figures. We have become more optimistic about Kabi’s profitability (IV drug’s brake to earnings sorted) and allowed for Helios’ higher than anticipated ..."
Pages
55
Language
English
Published on
21/06/22
You may also be interested by these reports :
03/02/26
Sartorius Stedim’s operations recovered well in FY25, driven primarily by high-margin consumables. Positive volume and mix effects expanded ...
03/02/26
Demant’s 2025 figures slightly exceeded estimates, driven by growth in Hearing Care and Diagnostics, particularly towards the year-end. However, ...
28/01/26
Getinge reported a soft Q4, with net sales and adjusted EBITA missing expectations and organic growth slowing to 1.2%. Order momentum also eased, ...
22/01/26
CZM’s Q1 FY 2025-26 preliminary release fell short of market expectations. Sales and profitability were adversely affected by both external and ...